Cargando…

The combined vaccination protocol of DNA/MVA expressing Zika virus structural proteins as efficient inducer of T and B cell immune responses

Zika virus (ZIKV) is a mosquito-borne pathogen with public health importance due to the high risk of its mosquito vector dissemination and the severe neurological and teratogenic sequelae associated with infection. Vaccines with broad immune specificity and control against this re-emerging virus are...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pérez, Patricia, Martín-Acebes, Miguel A., Poderoso, Teresa, Lázaro-Frías, Adrián, Saiz, Juan-Carlos, Sorzano, Carlos Óscar S., Esteban, Mariano, García-Arriaza, Juan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8284158/ https://www.ncbi.nlm.nih.gov/pubmed/34213405 http://dx.doi.org/10.1080/22221751.2021.1951624

Ejemplares similares

Deletion of Vaccinia Virus A40R Gene Improves the Immunogenicity of the HIV-1 Vaccine Candidate MVA-B
por: Pérez, Patricia, et al.
Publicado: (2020)

A Vaccine Based on a Modified Vaccinia Virus Ankara Vector Expressing Zika Virus Structural Proteins Controls Zika Virus Replication in Mice
por: Pérez, Patricia, et al.
Publicado: (2018)

An MVA Vector Expressing HIV-1 Envelope under the Control of a Potent Vaccinia Virus Promoter as a Promising Strategy in HIV/AIDS Vaccine Design
por: Pérez, Patricia, et al.
Publicado: (2019)

Removal of the C6 Vaccinia Virus Interferon-β Inhibitor in the Hepatitis C Vaccine Candidate MVA-HCV Elicited in Mice High Immunogenicity in Spite of Reduced Host Gene Expression
por: Q. Marín, María, et al.
Publicado: (2018)

Immunogenic Profiling in Mice of a HIV/AIDS Vaccine Candidate (MVA-B) Expressing Four HIV-1 Antigens and Potentiation by Specific Gene Deletions
por: García-Arriaza, Juan, et al.
Publicado: (2010)

Improving Adaptive and Memory Immune Responses of an HIV/AIDS Vaccine Candidate MVA-B by Deletion of Vaccinia Virus Genes (C6L and K7R) Blocking Interferon Signaling Pathways
por: García-Arriaza, Juan, et al.
Publicado: (2013)

Optimized Hepatitis C Virus (HCV) E2 Glycoproteins and their Immunogenicity in Combination with MVA-HCV
por: Marín, María Q., et al.
Publicado: (2020)

Low Immune Cross-Reactivity between West Nile Virus and a Zika Virus Vaccine Based on Modified Vaccinia Virus Ankara
por: Jiménez de Oya, Nereida, et al.
Publicado: (2022)

A Candidate HIV/AIDS Vaccine (MVA-B) Lacking Vaccinia Virus Gene C6L Enhances Memory HIV-1-Specific T-Cell Responses
por: García-Arriaza, Juan, et al.
Publicado: (2011)

Full efficacy and long-term immunogenicity induced by the SARS-CoV-2 vaccine candidate MVA-CoV2-S in mice
por: Lázaro-Frías, Adrián, et al.
Publicado: (2022)

The Scientific Response to Zika Virus
por: Martín-Acebes, Miguel A., et al.
Publicado: (2019)

COVID-19 Vaccine Candidates Based on Modified Vaccinia Virus Ankara Expressing the SARS-CoV-2 Spike Protein Induce Robust T- and B-Cell Immune Responses and Full Efficacy in Mice
por: García-Arriaza, Juan, et al.
Publicado: (2021)

Induction of Broad and Polyfunctional HIV-1-Specific T Cell Responses by the Multiepitopic Protein TMEP-B Vectored by MVA Virus
por: Perdiguero, Beatriz, et al.
Publicado: (2019)

A Novel MVA-Based HIV Vaccine Candidate (MVA-gp145-GPN) Co-Expressing Clade C Membrane-Bound Trimeric gp145 Env and Gag-Induced Virus-Like Particles (VLPs) Triggered Broad and Multifunctional HIV-1-Specific T Cell and Antibody Responses
por: Perdiguero, Beatriz, et al.
Publicado: (2019)

A Single Dose of an MVA Vaccine Expressing a Prefusion-Stabilized SARS-CoV-2 Spike Protein Neutralizes Variants of Concern and Protects Mice From a Lethal SARS-CoV-2 Infection
por: Pérez, Patricia, et al.
Publicado: (2022)

Relevance of oxidative stress in inhibition of eIF2 alpha phosphorylation and stress granules formation during Usutu virus infection
por: Blázquez, Ana-Belén, et al.
Publicado: (2021)

MVA-CoV2-S Vaccine Candidate Neutralizes Distinct Variants of Concern and Protects Against SARS-CoV-2 Infection in Hamsters
por: Boudewijns, Robbert, et al.
Publicado: (2022)

A Phase I Randomized Therapeutic MVA-B Vaccination Improves the Magnitude and Quality of the T Cell Immune Responses in HIV-1-Infected Subjects on HAART
por: Gómez, Carmen Elena, et al.
Publicado: (2015)

Antibody-Dependent Enhancement and Zika: Real Threat or Phantom Menace?
por: Martín-Acebes, Miguel A., et al.
Publicado: (2018)

High Quality Long-Term CD4(+) and CD8(+) Effector Memory Populations Stimulated by DNA-LACK/MVA-LACK Regimen in Leishmania major BALB/c Model of Infection
por: Sánchez-Sampedro, Lucas, et al.
Publicado: (2012)

Zika Virus: the Latest Newcomer
por: Saiz, Juan-Carlos, et al.
Publicado: (2016)

Insertion of Vaccinia Virus C7L Host Range Gene into NYVAC-B Genome Potentiates Immune Responses against HIV-1 Antigens
por: Nájera, José Luis, et al.
Publicado: (2010)

Lipid Metabolism as a Source of Druggable Targets for Antiviral Discovery against Zika and Other Flaviviruses
por: Martín-Acebes, Miguel A., et al.
Publicado: (2019)

Dengue Virus Strikes Back: Increased Future Risk of Severe Dengue Disease in Humans as a Result of Previous Exposure to Zika Virus
por: Martín-Acebes, Miguel A., et al.
Publicado: (2020)

Response: Commentary: Zika Virus: the Latest Newcomer
por: Saiz, Juan-Carlos, et al.
Publicado: (2016)

Pathogenicity and virulence of West Nile virus revisited eight decades after its first isolation
por: Saiz, Juan-Carlos, et al.
Publicado: (2021)

Host-Directed Antivirals: A Realistic Alternative to Fight Zika Virus
por: Saiz, Juan-Carlos, et al.
Publicado: (2018)

Potent HIV-1-Specific CD8 T Cell Responses Induced in Mice after Priming with a Multiepitopic DNA-TMEP and Boosting with the HIV Vaccine MVA-B
por: Perdiguero, Beatriz, et al.
Publicado: (2018)

Safety and vaccine-induced HIV-1 immune responses in healthy volunteers following a late MVA-B boost 4 years after the last immunization
por: C. Guardo, Alberto, et al.
Publicado: (2017)

Zika virus infection confers protection against West Nile virus challenge in mice
por: Vázquez-Calvo, Ángela, et al.
Publicado: (2017)

Correction: Safety and vaccine-induced HIV-1 immune responses in healthy volunteers following a late MVA-B boost 4 years after the last immunization
por: Guardo, Alberto C., et al.
Publicado: (2018)

Optimized vaccine candidate MVA-S(3P) fully protects against SARS-CoV-2 infection in hamsters
por: Abdelnabi, Rana, et al.
Publicado: (2023)

Antiviral Properties of the Natural Polyphenols Delphinidin and Epigallocatechin Gallate against the Flaviviruses West Nile Virus, Zika Virus, and Dengue Virus
por: Vázquez-Calvo, Ángela, et al.
Publicado: (2017)

Enhancement of the HIV-1-Specific Immune Response Induced by an mRNA Vaccine through Boosting with a Poxvirus MVA Vector Expressing the Same Antigen
por: Gómez, Carmen Elena, et al.
Publicado: (2021)

An MVA-based vector expressing cell-free ISG15 increases IFN-I production and improves HIV-1-specific CD8 T cell immune responses
por: Falqui, Michela, et al.
Publicado: (2023)

Poxvirus MVA Expressing SARS-CoV-2 S Protein Induces Robust Immunity and Protects Rhesus Macaques From SARS-CoV-2
por: Mooij, Petra, et al.
Publicado: (2022)

Tauopathy Analysis in P301S Mouse Model of Alzheimer Disease Immunized with DNA and MVA Poxvirus-Based Vaccines Expressing Human Full-Length 4R2N or 3RC Tau Proteins
por: García-Arriaza, Juan, et al.
Publicado: (2020)

Deletion of the Viral Anti-Apoptotic Gene F1L in the HIV/AIDS Vaccine Candidate MVA-C Enhances Immune Responses against HIV-1 Antigens
por: Perdiguero, Beatriz, et al.
Publicado: (2012)

Intranasal administration of a single dose of MVA-based vaccine candidates against COVID-19 induced local and systemic immune responses and protects mice from a lethal SARS-CoV-2 infection
por: Pérez, Patricia, et al.
Publicado: (2022)

Novel Nonnucleoside Inhibitors of Zika Virus Polymerase Identified through the Screening of an Open Library of Antikinetoplastid Compounds
por: Sáez-Álvarez, Yanira, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_t1apnmhgcnp77tq6th3622i8c2